OPKO Health, Inc. (OPK) is a multinational biopharmaceutical and diagnostics company, engaging in discovering, developing, and commercializing a variety of health care technologies. The company operates in two primary segments, namely pharmaceuticals and diagnostics.
Established in 1991 and headquartered in Miami, Florida, OPKO Health is dedicated to improving patient care and quality of life through innovative medicines and diagnostics. The company prides itself on exploring novel technologies and therapies to tackle the most challenging health issues worldwide. OPKO employs a diversified business model to achieve its core objectives, integrating an array of medical disciplines such as genetics, biochemistry, molecular biology, and pharmacology.
In its pharmaceutical segment, OPKO Health is actively involved in the research and development of several solutions for multiple diseases, specifically related to cardiology, nephrology, and neurology. This segment is known for its development of unique drugs in areas such as human growth hormone deficiency and chronic kidney disease. Furthermore, OPK offers Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency.
The diagnostics segment, on the other hand, is driven by BioReference Laboratories, one of the largest full-service laboratories in the US, which provides a broad testing portfolio to physicians, clinics, hospitals, and government entities. It also includes GeneDx — a world-renowned genetics and genomics laboratory — which specializes in diagnosing rare and ultra-rare disorders. Moreover, the company’s diagnostic capabilities extend to innovative solutions like the 4Kscore® test used to assess a male patient’s risk for aggressive prostate cancer.
Under the leadership of Dr. Phillip Frost, CEO, Chairman of the Board, OPKO Health, Inc. has experienced robust growth. The company (NASDAQ: OPK) has been publicly traded since 2007, and it has remained committed to delivering innovative healthcare solutions that not only address today's medical challenges, but also anticipate and prepare for future health needs.
OPKO Health, Inc. maintains a global presence, operating in more than 30 countries across North and South America, Europe, the Middle East, and Asia. To ensure continued innovation and growth, the company engages in strategic alliances, acquisitions, and investments in complementary businesses and technologies. These ventures significantly contribute to the company's goal of enhancing global health by continually pushing the boundaries of medical science and technology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
OPKO Health (NASDAQ:OPK) shares have moved above their 50-day moving average, trading at $1.67 with a volume of over 5.3 million shares. Despite beating quarterly earnings expectations by reporting a narrower loss and higher revenue, the company remains unprofitable with a negative net margin. Analyst ratings are mixed, with an overall "Hold" consensus and an average price target of $1.55.
Bank of New York Mellon Corp has acquired a new position in OPKO Health, Inc. (NASDAQ:OPK), purchasing 1.33 million shares valued at approximately $2.0 million, giving them a 0.18% stake. Other institutional investors also increased their holdings in OPKO Health, with a total of 64.63% of the stock owned by hedge funds and institutional investors. Despite mixed analyst ratings, OPKO Health recently surpassed quarterly earnings estimates, reporting an adjusted loss of $0.01 per share and revenue of $163.58 million, exceeding expectations.
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from five brokerages, with an average 12-month price target of $1.55. The company recently reported a quarterly loss of $0.01 per share, beating analyst expectations, and revenue of $163.58 million, which was up 4.3% year-over-year and also exceeded estimates. Institutional investors and hedge funds collectively own 64.63% of OPKO's stock.
AWM Investment Company Inc. recently acquired a new stake of 2,110,000 shares in OPKO Health, Inc. (NASDAQ:OPK), valued at approximately $3,165,000. This investment makes AWM Investment Company Inc. an owner of about 0.28% of OPKO Health. Other institutional investors also made new investments in OPKO Health, and the company has received a consensus "Hold" rating from analysts with a target price of $1.55.
OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movements. The Zacks Rank system, which uses earnings estimate revisions, aims to identify stocks with the potential for market-beating returns.